PUBLIC COMPANY
save$TNGXTango Therapeutics, Inc.
$TNGX23.89+9.77%Boston, MA, USupdated 13d ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- phase2Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- phase2Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
- phase2Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
- phase2Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
- phase2Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
🐶 Hiring Signal
Where Tango Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 17
News
- Verastem cancer drug shows early promise in small studyWall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.biopharma_dive · 1mo ago
- Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugPlus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will…endpoints · 5mo ago
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that